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ABSTRACT 
DHEA ACTION IS MEDIATED BY MULTIPLE RECEPTORS AND 
METABOLITES 
ADVISOR: RUSSELL A. PROUGH Ph.D. 
BY KRISTY K. MICHAEL MILLER 
MAY 2004 
Dehydroepiandrosterone (DHEA) is a C-19 adrenal steroid and the most abundant 
circulating hormone in humans. Since circulating levels decline in late adulthood, 
treatment of humans with DHEA has been suggested to have beneficial health effects. 
Although the mechanism of action is unknown, DHEA may be metabolized to active 
metabolites that exert their physiological effects by receptor-mediated processes and cell 
signaling pathways. The purpose of this study was to investigate the mechanistic 
processes ofDHEA action. 
Since DHEA may exert its pleotropic effects by being metabolized to biologically 
active species, a GC/MS method was developed to quantify the liver microsomal 
metabolism ofDHEA of various species and identify the P450 enzymes responsible for 
metabolism. 16a-hydroxy-DHEA and 7a-hydroxy-DHEA were formed in rat, hamster, 
pig and human. CYP3A4 and CYP3A5 formed 7a-hydroxy-DHEA, 16a-hydroxy-
DHEA, and the unique human metabolite, 7j3-hydroxy-DHEA, while the fetal enzyme 
CYP3A 7 fonned only 16a-hydroxy and 7p-hydroxy-DHEA. By using this method to 
examine the metabolite profiles of various P450s, the developmental expression patterns 
VI 
of the human cytochrome P4503A forms could be classified and therefore have 
significant clinical relevance. 
Nuclear receptors transduce the effects of hormones into transcriptional 
responses. DHEA and metabolites were screened in a cell-based assay to determine the 
interaction with estrogen receptors alpha and beta (ERa and ERP). DHEA, DHEA-S, 
and androstendiol activated ERa, while DHEA, 7-oxo-DHEA, androstenedione and 
androstenediol activated ERP demonstrating ER is activated directly by DHEA and some 
metabolites. 
These and other studies from our laboratory demonstrate that DHEA is 
metabolized into various monohydroxylated metabolites. DHEA and metabolites directly 
activate ER as well as the pregnane X receptor (PXR). Additionally, DHEA has been 
shown to activate another nuclear receptor, peroxisome proliferator activated receptor 
alpha (PP ARa) in vivo. This research suggests that DHEA action is mediated by multiple 
receptors and metabolites with various biological activities, comprising of a complex 
mode of action ofDHEA. 
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Dehydroepiandrosterone (5-androsten-3~-01-17-one) is a naturally occurring C-19 
adrenal steroid derived from cholesterol by a series of cytochrome P450 mono-oxygenase 
and hydroxysteroid dehydrogenase catalyzed reactions (Figure 1). 
Dehydroepiandrosterone (DHEA) is secreted primarily by the zona reticularis of the 
adrenal cortex of humans and other primates. DHEA secretion is controlled by 
adrenocorticotrophin (ACTH) and other pituitary factors (Nieschlag et al., 1973). The 
adrenal cortex secretes 75-90% ofthe body's DHEA, with the remainder being produced 
by the testes and ovaries (Vermeulen, 1980 and de Peretti and Forest, 1978 and Nieschlag 
et aI., 1973). 
Primates produce DHEA by the ~5-steroidogenic pathway in which the double 
bond at the C-5 and C-6 position is maintained. In this process, the P450 side-chain-
cleavage (P450scc or P45011Al) converts cholesterol to pregnenolone. Pregnenolone is 
then hydroxylated at the C-17 position followed by a two carbon side chain cleavage by 
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Figure 1. Biosynthesis of DHEA and other steroids in humans. The enzymes responsible for conversions are italicized, the listing 
of more than one enzyme indicates a multisystem process. HSD, hydroxysteroid dehydrogenase; HSS, hydroxysteroid sulfatase; KSR, 
ketosteroid reductase; R, reductase; sec, side chain cleavage enzyme; SH, sulfohydrolase (Figure adapted from Kroboth et al. J Clin 
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Figure 2. The 114 and 115 Steroidogenic Pathways. (Figure adapted from Conley and 
Bird. Biol.Reprod. (1997) 56:789-799). 
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Little or no DHEA is produced by the adrenal of nonprimate species, such as mice 
and rats. Instead, nonprimates produce sex steroids via the d 4-steroidogenic pathway in 
which cholesterol is converted to pregnenolone by P450scc . Pregnenolone is then 
converted to progesterone by 3p-hydroxysteroid dehydrogenase (3P-HSD) and it is taken 
up by peripheral steroidogenic tissues and converted to androstenedione by P450C17 
(Figure 2). 
Although DHEA is the primary sterol in these biosynthetic pathways, DHEA is 
largely found in circulation in its sulfated fonn, DHEA 3p-sulfate (DHEA-S), which can 
be interconverted with DHEA by DHEA sulfotransferases and hydroxysteroid sulfatases 
(Regalson et ai., 1994). Although DHEA-S is the hydrophilic storage fonn that circulates 
in the blood, as stated previously, DHEA is the principle fonn used in steroid hormone 
synthesis. Therefore, the differences in tissue-specific expression ofDHEA 
sulfotransferase and steroid sulfatase determine the balance between DHEA 
interconversions with DHEA inactivation (Allolio and Arlt, 2002). 
In humans, plasma DHEA concentrations are found in the range of 1-4 ng/mL 
(0.003 - 0.015J.lM) (Table I), but circulating DHEA-S concentrations are much greater 
(Barrett-Connor E et al., 1986 and Hopper and Yen, 1975). Bird et ai., (1984) reported 
that 64% and 74% of the daily production ofDHEA is converted to DHEA-S in women 
and men, respectively, but only about 13% ofDHEA-S is hydrolyzed back to DHEA. 
On a molar basis, circulating DHEA-S concentrations are 250 and 500 times higher (~1 -
10 J.lM) than those ofDHEA in women and men, respectively (Labrie F et ai., 1995). 
The abundant circulating concentrations ofDHEA-S are due in part because DHEA is 
4 










TABLE I. Physiological concentrations of DHEA-S. 
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cleared from the blood at a rate of approximately 2000 Llday, whereas DHEA-S 
clearance is about 13 Llday (Lephart et al., 1987). Additionally, DHEA has a half-life in 
blood of about 1 to 3 hours, while DHEA-S has a half-life of 10 to 20 hours (Rosenfeld et 
at., 1975). Clearance rate is defined as the volume of plasma that would contain the 
amount of drug excreted per unit volume. Therefore, clearance expresses the rate of drug 
removal from the plasma, but not the amount of drug eliminated. The clearance rates of 
DHEA and its sulfate are also influenced by their protein-binding characteristics. For 
example, DHEA is weakly bound to albumin, while DHEA-S is strongly bound to 
albumin. 
PHYSIOLOGICAL AND PHARMACOLOGICAL CONCENTRATIONS OF 
DHEA 
In its sulfated form, DHEA is the most abundant circulating sterol in humans, 
followed by androstenedione. During fetal development, plasma DHEA-S levels are 
around 100-200 llg/dL (3-7 IlM), but fall rapidly after birth and remain low for the first 
five years of life. Blood DHEA levels then rise and peak around 300 Ilg/dL (10 IlM) 
during the second decade of postnatal life, followed by an age-dependent decline. 
Additionally, there are clear gender differences in circulating levels of DHEA-S with 
higher levels found in men than women (Figure 3). 
Labrie and coworkers (1987) suggest that a decrease in 17,20-desmolase (see 
Figure 1) activity may be responsible for the dramatic age-related reduction in DHEA 








Figure 3. Variation of circulating DHEA-S levels throughout human life. (Figure 
adapted from Rainey et al. Trends Endocrinol. Metab. (2002) 13:234-239). 
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secretion are not observed by other steroid hormones, suggesting that the mechanisms 
regulating DHEA formation are unique (Rainey et al., 2002). In contrast, serum 
cholesterol levels tend to increase with age, while other steroid hormones, decline more 
slowly relative to DHEA with age. The decline in circulating levels ofDHEA and its 
sulfate derivative appear to be inversely correlated to the rise in cholesterol and the 
pathophysiological effects of aging (Barret-Conner et aI., 1999). 
Because the decline in DHEA is associated with some of the pathophysiological 
effects of aging, many people supplement their own DHEA levels with exogenous DHEA 
and even refer to DHEA as the "fountain of youth hormone." When administered, 
DHEA is usually in an encapsulated powder in two or three divided doses. Although 
appropriate physiological doses are not well defined and differ in men and women, many 
clinical studies have been conducted using 50 mg/day for women and 100 mg/day for 
men. 
Currently, DHEA is available over-the-counter as a dietary supplement and is 
therefore not regulated by the Food and Drug Administration. However, this has not 
always been the case. DHEA was once marketed for weight loss and in 1985, the FDA 
banned over-the-counter sales ofDHEA. DHEA is still outlawed by the International 
Olympic Committee and the National Collegiate Athletic Association, but since the 
passage of the Dietary Supplement Health and Education Act of 1994, DHEA has again 
been widely available in health food stores in the US (and elsewhere) where is it 
marketed as a dietary supplement. There are fewer regulations over the rule of nutritional 
products than with nonprescription or prescription drugs. For example, expiration dates 
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are not required and there are no chemical standards for the product, and nutritional 
supplements, such as DHEA, can be sold unless the FDA proves that they are unsafe. 
DHEAACTION 
Since DHEA and DHEA-S have higher serum concentrations than other 
hormones, DHEA has been viewed as a potential androgen, as a storage repository for 
androgens and precursor to sex hormones (Ebeling and Koivisto, 1994). However, other 
than being a precursor to sex hormones and playing a role as such in the development of 
pubic and axillary hair and the development and maintenance of immunocompetence, a 
physiological role for DHEA has not been defined to date. DHEA is produced by the 
adrenal gland in humans and is taken up by several tissues, including brain, liver, kidney, 
and gonads, and is metabolized to androstenediol, testosterone, estrogen and other 
biologically active steroids, depending on the tissue. The work of Labrie et al. (1987) 
suggest that more than 30% of total androgen in men and over 90% of estrogen in 
postmenopausal women are derived from peripheral conversion ofDHEA-S to DHEA. 
Treatment with high doses of exogenous DHEA has been shown to have 
beneficial effects on lowering body fat and in modulating the effects of diabetes, 
atherosclerosis, and obesity in rodent models (Y oneyama et aI., 1997). Additionally, 
DHEA has chemopreventative affects when administered to rodents in low doses (Rao et 
ai., 1992 and Lubet et ai., 1998). It is purported that in humans, DHEA may also modify 
the immune response, alter chemical carcinogenesis, reverse the deleterious effects of 
glucocorticoids, as well as display neuroprotective and memory-enhancing effects 
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(Robinzon et at. 2003, Ben-Nathan et al. 1992, and Lapchak et at. 2001). However, the 
mechanism of these processes is not known. 
Since DHEA is marketed as a nutritional supplement in the US, allowing 
companies to bypass the rigorous clinical trials required for FDA approval for medicinal 
use, DHEA has not been subject to the strict quality control measures applied to other 
drugs. Although DHEA is purported to have many beneficial effects, there is little 
evidence to support the use ofDHEA and there has been no clinical trial that clearly 
substantiated the evidence and safety for DHEA supplements. Therefore, with the current 
utilization ofDHEA as a dietary supplement purported to protect against diabetes, 
atherosclerosis, obesity, lupus and arthritis, the mechanism of action of this sterol and its 
metabolites is important to study. 
DHEA METABOLITES 
As stated previously, treatment with exogenous DHEA has been shown to have 
many beneficial effects. The mechanism by which DHEA exerts its beneficial effects 
may involve the metabolism ofDHEA to multiple biologically active metabolites 
(Fitzpatrick et ai., 2001 and Marwah et al. 2002). Miller et al. (2004) showed that human 
liver microsomal metabolism ofDHEA produced 7a-OH-DHEA, 16a-OH-DHEA as 
well as 7~-OH-DHEA. 
The hydroxylated metabolites ofDHEA have been shown to exhibit biological 
activity. For instance, Morfin and Starka (2001) showed that 7a- and 7~ -OH-DHEA 
were efficient in preventing the nuclear uptake of eH]dexamethasone-activated 
glucocorticoid receptor in brain cells demonstrating a key event for the neuroprotection 
10 
conferred by neurosteroids. Additionally, 16a-OH-DHEA is known to be the precursor 
of fetal 16a-hydroxylated estrogens which are the main phenolic steroids produced 
during pregnancy (Hampl and Starka, 2000) 
CYTOCHROME P450 
Cytochrome P450s (CYPs) are a family of he mop rote ins that were named as such 
because a strong absorption band at 450 nm is observed when CO binds tightly to the 
ferrous heme of the protein. P450s catalyze the NADPH and 02-dependent 
monooxygenation of a wide variety of compounds by incorporating one atom of 
molecular oxygen into the substrate and one atom into water. P450s are capable of 
catalyzing an extraordinary range of biochemical reactions, from the synthesis of 
cholesterol, bile acids, and steroid hormones to the oxidative metabolism of drugs and 
xenobiotics at carbon, nitrogen, sulfur and phosphorous centers. 
There are two different kinds of electron transfer chains observed for mammalian 
P450s. Some P450s are found in the mitochondrial inner membrane and some are found 
in the endoplasmic reticulum (ER). Both types of P450s are membrane-bound proteins. 
In the catalytic cycle for P450 reactions (see Figure 4), NADPH-cytochrome P450 
reductase separately donates electrons to the P450. Two electrons are acquired from 
NADPH and transferred singly from FAD to FMN of the reductase, and then to the P450 
heme iron (Nelson, online). 
CYP genes are arranged into families and subfamilies based on the percentage of 
amino acid sequence identity. Currently, there are more than 270 different CYP gene 
11 
Figure 4. Generalized catalytic cycle for P450 reactions. (Figure adapted from 
Guengerich J Bioi. Chern. (1991) 266:10019-10022). 
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families and 18 recorded in mammals. The human CYP superfamily is composed of 57 
genes (Nebert and Nelson, online). These genes code for enzymes that have been known 
to have toxicological and pharmacological roles involved in metabolizing drugs, 
xenobiotics, vitamins, steroids, and fatty acids (Table II). 
Human P450s that are responsible for the metabolism of toxicological and 
pharmacological compounds are almost exclusively in the CYPl, CYP2, CYP3, and 
CYP4 families. However, members of the CYP3A subfamily are the most abundantly 
expressed P450 enzymes in the human liver and gastrointestinal tract and are known to 
metabolize more than 120 frequently prescribed drugs, as well as steroids and bile acids 
(Nebert and Jorge-Nebert, 2002). Four human CYP3A enzymes have been identified; 
CYP3A4, CYP3A5, CYP3A7, and CYP3A43. CYP3A4 and CYP3A5 are the most 
abundantly expressed P450 enzymes and are expressed in adult human liver, while 
CYP3A 7 is most prominently expressed in fetal liver. CYP3A43 is expressed at much 
lower levels in the human liver and its function is not known (Komori M et al., 1989). 
Many P450s function as steroid hydroxylases. For instance, members of the 
CYP7, CYP8, CYP27, CYP39, and CYP46 family of enzymes playa role in bile acid 
synthesis by hydroxylating cholesterol and subsequently oxidizing the resulting eight 
carbon side chain to generate water soluble bile acids. Additionally, members of the 
CYP 11, CYP 17, CYP 19 and CYP21 families participate in steroidogenesis, generating 
androgens and estrogens from cholesterol. There are other P450s such as the CYP4 
family that playa role in the metabolism of fatty acids, arachidonic acid, leukotrienes, 
13 
Human P450 Rat Analog Substrate/Function 
lAl lAl Foreign chemicals, arachidonic acid, eicosanoids 
lA2 lA2 Foreign chemicals, arachidonic acid, eicosanoids 
lBl 1B1 Foreign chemicals, arachidonic acid, eicosanoids 
2A6 2A2 Foreign chemicals, arachidonic acid, eicosanoids 
2B6 2Bl Foreign chemicals, arachidonic acid, eicosanoids 
2C8 2Cll Foreign chemicals, arachidonic acid, eicosanoids 
2C9 2Cl2 Foreign chemicals, arachidonic acid, eicosanoids 
2C19 2C13 Foreign chemicals, arachidonic acid, eicosanoids 
2D6 2D2 Foreign chemicals, arachidonic acid, eicosanoids 
3A4 3A23 Foreign chemicals, arachidonic acid, eicosanoids 
3A5 3A9 Foreign chemicals, arachidonic acid, eicosanoids 
3A7 3Al8 Foreign chemicals, arachidonic acid, eicosanoids 
4AlI 4Al Fatty acids, arachidonic acid, eicosanoids 
7Al 7Al Cholesterol, bile acid synthesis 
8Bl 8Bl Prostacyc1in synthase, bile acid synthesis 
lIBI lIBI Steroidogenesis 
17Al 17Al Steroid 17a-hydroxylase, 17120 lyase 
19A1 19A1 Aromatase to form estrogen 
21A2 21A2 Steroid 2l-hydroxylase 
27Al 27Al Bile acid biosynthesis, vitamin D3 hydroxylations 
39Al 39Al 24-hydroxycholesterol, 7a-hydroxylase 
46Al 46Al Cholesterol 24-hyroxylase 
TABLE II. Substrates and functions of human and rat CYP genes. (Table adapted 
from Nebert and Russell (2002) The Lancet. 360:1155-1162). 
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prostaglandin, epoxyeicosatrienoic acids (EETs), hydroxyeicosatetraenoic acids 
(HETEs), and hydroperoxyeicosatetraenoic acids (HPETEs) (Nebert and Russell, 2002). 
The products of many P450 reactions function as ligands for nuclear receptors. 
For example, P450s catalyze both the formation and degradation of many nuclear 
receptor ligands. Therefore, nuclear receptors playa key role in the regulation ofP450 
gene transcription by serving as receptors for a diversity of ligands. 
NUCLEAR RECEPTORS 
The nuclear receptor superfamily consists of an array of transcription factors that 
transform extracellular and intracellular signals into cellular response by inducing the 
transcription of nuclear receptor target genes. Unlike hormones for cell surface receptors, 
nuclear receptors transduce the effects of small, lipophilic hormones, such as 
glucocorticoids, mineralocorticoids, sex steroids, and thyroid hormones into 
transcriptional responses (Mangelsdorf and Evans, 1995). 
The nuclear receptor superfamily is comprised of steroid nuclear receptors, 
orphan nuclear receptors and (retinoic X receptor) RXR heterodimers (Figure 5). Steroid 
nuclear receptors are receptors for which the hormonal ligand has been identified, 
whereas the term orphan nuclear receptor was coined to describe gene products that 
appeared to belong to the nuclear receptor family on the basis of gene sequence 
similarity, or which the ligand(s), if required are unknown. In addition to steroid 
receptors and orphan receptors, there are the RXR heterodimers which are nuclear 
receptors that form heterodimers with the retinoid X receptor. The nuclear receptors that 
are known to heterodimerize with RXR require RXR for DNA-binding. The activation 
15 
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Figure 5. Structure/function organization of nuclear receptors. (Figure adapted from 
Olefsky (2001) Journal Bioi. Chern. 276:36863·36864) 
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state ofRXR varies among heterodimers. For instance, RXR can be completely inactive 
in nonpermissive heterodimers, such as thyroid hormone receptor (TR) and the vitamin D 
receptor (VDR) (Kurokawa et aI., 1994), or be freely active in permissive heterodimers 
with PPAR (Kliewer et al., 1992). 
Nuclear receptors share similarity with classical steroid hormone receptors in their 
DNA binding domain (DBD), and ligand binding domain (LBD). Nuclear receptors are 
comprised of certain regions of conserved function and sequence. There are common 
structural features for all nuclear receptors (Figure 5), such as the DNA binding domain 
(region C) which is the most highly conserved domain. A variable length hinge domain 
is located between the DBD and LBD (region D). The N-terminal region contains the 
Activation Function-l domain (region NB) which is a ligand-independent transactivation 
domain. About 250 C-terminal residues constitute the LBD (region E) that also includes 
the site for hormone-inducible transcription activating function is present in the LBD 
(AF-2). Additionally, many receptors contain a variable length C-terminal region (region 
F) whose function is poorly understood. 
A number of molecules that were once thought of as metabolic intermediates are 
in fact ligands for nuclear receptors, thereby providing a mechanism for coupling 
metabolic pathways with changes in gene expression. For example, ligands which 
activate pregnane X receptor (PXR), constitutive androstane receptor (CAR), liver X 
receptor (LXR), farnesoid X receptor (FXR), and RXR (steroids and xenobiotics, 
androstanes, hydroxycholesterols, bile acids, and 9-cis retinoic acid, respectively) have 
been used to identify the biological roles of the receptors and provided insight into the 
regulation of glucose, lipid and drug metabolism. Additionally, the role of nuclear 
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receptors in human diseases and their importance as therapeutic targets have implications 
in human biology, as well as, understanding and development of new drug treatments 
(Kliewer et at, 1999). 
ESTROGEN RECEPTOR 
The estrogen receptor (ER) is a member of the nuclear receptor superfamily that 
mediates the biological responses of estrogens and is perhaps one of the most well 
defined nuclear receptors. Estrogens influence a wide range of physiological processes 
including growth, differentiation, and the development of reproductive tissues, bone 
density maintenance, liver, fat and bone cell metabolism, cardiovascular and neuronal 
activity as well as embryonic and fetal development. Estrogens also influence several 
pathological processes such as breast, endometrium and ovarian cancers, osteoporosis, 
atherosclerosis and Alzheimer's disease (Nonnan and Litwack, 1987). Estrogens have 
both desirable and hannful effects on certain pathological processes, but the mechanisms 
of these processes are poorly understood. 
The biological actions of estrogens are mediated by estrogen binding as a ligand 
to one of two specific estrogen receptors (ERs), ERa (NR3Al) and ERP (NR3A2). 
Although they both mediate the effects of estrogen, the two receptors have unique and 
distinctly different patterns of expression within the human (Figure 6). 17p-estradiol (E2) 
is the typical ER ligand. The classic E2 target tissues have a high ERa content and 
respond to E2 challenge with increases in transcription of certain genes containing well-
documented estrogen responsive elements (EREs) 5'-GGTCAnnnTGACC-3' (n is any 
nucleotide) within the promoter region or 5'- flanking region of the target gene (Klinge, 
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Figure 6. Localization of ER isoforms. ERa and ER~ have distinctly different 
locations and concentrations within the human (Figure adapted from Gustafsson. (1999) 
1. Endocrinol. 163:379-383). 
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2001). The classic E2 target tissues defined in the past are the uterus, mammary gland, 
placenta, liver, central nervous system (eNS), cardiovascular system, and bone. In other 
target tissues, the expression of ERa is either very low or non-detectable, while ERP is 
highly expressed. ERP target tissues include prostate, testis, ovary, pineal gland, thyroid 
gland, parathyroids, adrenals, pancreas, gallbladder, skin, urinary tract, lymphoid and 
erythroid tissues (Gustafsson, 1999). Since ERa and ERP are differentially expressed 
among tissues, both subtypes of the receptor are regulated in a tissue- and/or cell-specific 
manner (Zhou et. al., 2001). 
ERa was cloned in 1986 and ten years later, ERP was discovered in rat prostate 
(Figure 7). There is a 97% amino acid identity between the two receptors in the DBD, 
suggesting that ERP can recognize and bind to similar EREs as ERa. However, because 
the LBD homology is only 47% between ERa and ERP, each receptor may have a 
distinct spectrum of ligands by which they are activated (Kong et. aI., 2003 and Paech et 
al., 1997). Indeed, ERP shows higher affinity for a number of phytoestrogens compared 
to ERa. 
In absence of ligand, ERa is localized within an inhibitory heat shock protein 
complex. Upon ligand binding to an estrogenic compound, ER changes its conformation, 
causing displacement of heat shock proteins, recruitment of coregulator proteins and 
other transcription factors (Rachez and Freedman, 2001). The formation of this 
preinitiation complex promotes the binding of ER as a homodimer or heterodimer to 
EREs. Once bound to DNA, transcription is initiated, thereby regulating the activation or 
repression of ER target genes. In addition to direct binding of ER to DNA, ER can also 
regulate transcription via a "tethering" mechanism in which ER interacts with other DNA 
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Figure 7. Domain structure representation of human ERa and ER~ isoforms. 
(Figure adapted from Kong et al. (2003) Biochemical Society Transactions 31 :56-59) 
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bound transcription factors, i.e. AP-1 (Kushner, 2000), NF-KB (McKay and Cidlowski, 
1998), and SP-1 (Safe, 2001) that stabilize the DNA and recruit other coactivators to the 
transactivation complex (Webb et aI., 1999). 
The ligand-dependent transcriptional activity of ER is mediated by various 
domains within the receptor sequence. Although ERa and ER~ share only 59% 
homology within the LBD, the DBD is highly conserved in both ERa and ER~, and 
contains two distinct zinc fingers that playa critical role in DNA sequence specific 
receptor binding and receptor dimerization. The AF-1 domain ofER has been found to 
be stimulated through phosphorylation by mitogen-activated protein kinase (MAPK) 
(Kato et aI., 1995). However, there is little or no sequence homology between the two 
receptors within the N-terminal region due to the truncated N-terminal region of ER~ 
receptor (Figure 7) resulting in a lack ofER~ AF-1 activity. 
Due to the lack of sequence homology in the N-terminal AF-1 and C-terminal 
AF-2 regions, the two receptors not only exhibit distinctive response to estrogenic 
compounds, but ER~ can function as a dominant inhibitor of ERa transcriptional activity 
(Hall and McDonnell, 1999). Because their AF domains exhibit distinct properties, AFs 
regulate ERs in a cell and promoter specific manner (Matthews and Gustafsson, 2003). 
Therefore, although ER mediates the cellular responses of an estrogenic stimulus, the 
functional response is dependent on tissue, pathway of regulation, and protein in which 
the receptor action is mediated. 
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CHAPTER II 
STEREO- AND REGIOSELECTIVITY ACCOUNT FOR THE DIVERSITY OF 
DHEA METABOLITES PRODUCED BY LIVER MICROSOMAL 
CYTOCHROMES P450 
(This chapter was published in Drug Metabolism and Disposition 32:305-313) 
INTRODUCTION 
Dehydroepiandrosterone (DHEA) is a 19-carbon steroid derived from cholesterol 
by a series of cytochrome P450 mono-oxgenase and hydroxysteroid dehydrogenase-
dependent reactions (Conley and Bird, 1997). In its sulfated form, DHEA is the most 
abundant circulating steroid in humans and is a precursor to the sex steroids, estrogen and 
testosterone. Levels ofDHEA-S in the circulation are high during fetal development (1-5 
~M), but fall rapidly after birth and remain low for the first five years of life. DHEA and 
DHEA-S levels in blood then rise and peak during the second decade (~10 ~M), followed 
by an age-dependent decline for individuals age 30 or above (Herbert, 1995). The 
developmental changes in circulating levels DHEA and DHEA-S in the blood are not 
paralleled by other steroid hormones, suggesting the mechanisms regulating DHEA 
formation in adrenal are unique (Rainey et ai., 2002). In contrast, serum cholesterol 
levels tend to increase with age, while DHEA levels decline with age. The decline in 
circulating levels ofDHEA and its sulfate derivative appear to be inversely correlated to 
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the rise in cholesterol and the pathophysiological effects of aging (Barrett-Connor et al., 
1999). 
Treatment with exogenous DHEA has been shown to have beneficial effects in 
lowering body fat and modulating the effects of diabetes, atherosclerosis, and obesity in 
rodent models (Y oneyama et al., 1997). Additionally, DHEA has cancer 
chemopreventative actions when administered to rodents in low doses (Lubet et al., 1998; 
Rao et ai., 1992). However, at higher doses, DHEA can cause peroxisome proliferation 
resulting in hepatomegaly (Frenkel et ai., 1990) and subsequent development of 
hepatocarcinomas (Rao et ai., 1992). With the current utilization ofDHEA as a dietary 
supplement proposed to protect against diabetes, atherosclerosis, obesity and arthritis, the 
mechanism of biological action of this sterol and its metabolites have become important 
to study. 
Since the rat adrenal does not express CYP17, the rat does not produce DHEA in 
the adrenal (Kalimi and Regelson, 1990;Voutilainen et aI., 1986). However, DHEA is 
formed in the human adrenal and is a precursor to sex steroids (Figure 1). In humans, 
DHEA circulates as the 3p-sulfate conjugate DHEA-S until taken up by target tissues 
where it is then converted to DHEA by sulfatases (Burstein and Dorfman, 1963). In 
steroidogenic tissues, DHEA is metabolized to androgens and estrogens by 
hydroxysteroid dehydrogenase reactions. However, other oxidative pathways of DHEA 
metabolism have not been extensively studied. 
The beneficial effects resulting from exogenous administration ofDHEA may 
involve the metabolism ofDHEA to multiple biologically active species (Fitzpatrick et 
al., 2001; Marwah et ai., 2002). Fitzpatrick et ai. (2001) used LC/MS to identify 7u- and 
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16a-OH-DHEA as the major metabolites produced by the human along with another 
mono""hydroxylated DHEA species whose position of hydroxylation was unknown. The 
purpose ofthis study was to quantify the liver microsomal metabolism ofDHEA by 
various species and elucidate the P450s responsible for the metabolism ofDHEA. A 
sensitive GC/MS method was developed to identify and quantify all the metabolites 
produced by the metabolism ofDHEA. The results of this study provide a method for 
quantifying the microsomal metabolism ofDHEA and demonstrate the regio- and 
stereoselectivity of specific CYPs that accounts for the unique DHEA metabolite profiles 
formed by various species. 
MATERIALS AND METHODS 
Chemicals. DHEA, 7a-hydroxy-DHEA, 7p-hydroxy-DHEA, 16a-hydroxy-DHEA, 
androstenedione and etiocholanolone were purchased from Steraloids, Inc. (Wilton, NH). 
Human liver samples were kindly provided by F. Peter Guengerich (Center for Molecular 
Toxicology, Vanderbilt University School of Medicine, Nashville, TN). The use of these 
human tissue samples were approved by the Institutional Review Boards of the 
University of Louisville and Vanderbilt University. The human P450 baculovirus system 
used to provide functional CYP preparations was designed to express both CYPs and 
P450 oxidoreductase using a suspension culture ofbaculovirus-infected insect cells 
(Rushmore et al., 2000). Fresh membrane fractions were prepared at Merck Research 
Laboratories and the metabolic assays were performed at the University of Louisville. 
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Animals. Male Sprague-Dawley rats (225 g, HSD:SD) from Harlan, Indianapolis were 
maintained on control diet (AIN-76A ICN Biomedicals, Cleveland, OH) for 5 days. 
Animals were anesthetized with CO2 and the livers perfused with 0.9% sodium chloride 
prior to dissection from the body. Livers were cut into small pieces and then 
homogenized in a Potter-Elvehjem homogenizer containing 4 volumes of 50 mM 
potassium phosphate buffer, pH 7.4, containing 0.25 M sucrose per gram liver. 
Microsomal fractions was isolated by differential centrifugation as described by Remmer 
et al. (1966). Microsomal fractions were resuspended in 0.1 M Tris-HCl buffer (pH 7.4), 
containing 0.25 M sucrose and sedimented a second time. The final preparation was 
resuspended in Tris-HCl buffer containing sucrose and 10% glycerol and stored at -70°C 
for up to 3 months without loss of activity. Protein concentrations were determined by 
measuring formation ofbicinchoninic acid Cu1+ complex at 562 nm. 
NADPH: cytochrome c oxidoreductase assay. The baculovirus expression system 
allows coexpression of both P450 and its flavoprotein oxidoreductase (Rushmore et al., 
2000) and NADPH: cytochrome c oxidoreductase activity was measured to characterize 
the enzymatic efficiency in this baculovirus-expression system. The reactions were 
carried out at 25°C in 0.05 M potassium phosphate buffer, pH 7.4 containing 100 ~M 
NADPH, 40 ~M cytochrome c, and aliquots of the P450 sample being characterized. The 
absorbance change at 550 nm was monitored at 25° C with a Cary 50 Bio UV-Visible 
spectrophotometer assuming a molar absorptivity of21,100 M-1 cm-1 (Masters et al., 
1967). The P450/P450 oxidoreductase ratios for CYP3A4, CYP3A5, CYP3A7, 
CYP2B6, and CYP2Bl preparations are shown in Table III. The ratios for all CYPs 
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TABLE III 
Content of P450 and NADPH:Cytochrome P450 Oxidoreductase in various 
baculovirus preparations. 
Sample P4S0 Concentration P4S0 Oxidoreductase P4S0/POR Ratio 
(nmol/mL) (nmollmL) 
-..... --.-.-----~-------.-,-----.. ---,-------......... -.--,-----.---."--------~~, ... --,.-..... ------------.. ,-.-.... - ...... _._ .... - .............. _-. 
CYP3A4 2.0 1.9 1.0 
CYP3AS 1.0 O.S 2.0 
CYP3A7 1.5 0.8 1.8 
CYP2B6 1.5 1.4 1.1 
CYP2Bl 1.0 1.3 0.8 
The baculovirus expression system allows co-expression of both P450 and its 
flavoprotein oxidoreductase. The P450 oxidoreductase activity was used to calculate the 
concentration of flavoprotein using the factor 1,360 /lmol cytochrome c reduced per 
minute per /lM of oxidoreductase protein (Yasukochi and Masters, 1976). The ratios for 
all P450s are approximately equal or more than one, indicating that the content ofP4S0 
oxidoreductase is most likely not rate limiting. 
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prepared were near 1, indicating that the content ofP450 oxidoreductase in the 
preparations was likely not rate-limiting in the reaction. 
DHEA metabolism. Hepatic microsomal protein fractions or recombinant CYPs were 
incubated in 2 mL reaction mixtures containing 0.1 M Tris-HCI buffer, pH 7.5, 1 mM 
EDTA, 10 mM MgS04 and an NADPH-regenerating system consisting of 1 mM p-
NADPH, 0.8 mM isocitrate, and 0.1 D/ml ofisocitrate dehydrogenase. The samples were 
oxygenated by blowing pure O2 into each tube for 15 seconds. The microsomal fractions 
and regenerating system were preincubated 4 min. at 37°C prior to addition of 50 IlM 
DHEA. After incubation for specified times at 37°C in a shaking water bath, the 
reactions were terminated at various times by adding equal volumes of chilled ethyl 
acetate. The rates of product formation were measured in the linear portion of the time 
course. The metabolites were extracted from the aqueous phase three times with ethyl 
acetate and dried under a stream ofN2 gas at room temperature. 
Derivatization of samples. DHEA and its metabolites were prepared for GCIMS 
analysis by adding 50 III ofMOX to the dried metabolites overnight at room temperature 
to derivatize any oxo-functional groups. The sample was dried under a stream ofN2 gas 
at room temperature, 50 III ofBSTFA-TMS was added, and the solution incubated at 
70°C to derivatize hydroxyl groups. An internal standard, etiocholanolone, was added to 
each sample prior to extraction with ethyl acetate and analysis by GC/MS. 
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Gas chromatography/mass spectrometric analysis. Single quadrapole GC/MS was 
utilized to resolve and quantify the DHEA metabolites, using etiocholanolone as an 
internal standard. Initial experiments assessed linearity of the reaction with time and 
protein concentration. Reactions were carried out with microsomes from rat, pig and 
hamster, as well as five different human samples to assess potential inter-individual 
variability in product formation. Derivatized DHEA and metabolites were analyzed with 
an HP5890/HP5973 GC/MS system (Hewlett-Packard, Palo Alto, CA). Separation was 
achieved by using a bonded-phase capillary column (DB-17MS, 15 m x 0.25 mm LD. x 
0.25 /-lm film thickness) from J&W Scientific (Folsom, CA). The GC injection port and 
interface temperature was set to 280°C, with helium carrier gas maintained at 14 psig. 
Injections were made in the splitless mode with the inlet port purged for 1 min following 
injection. The GC oven temperature was held initially at 100°C for 0.5 minute, increased 
at a rate of 30°C min-1 to 325°C, increased at a rate of 2°C min-1 to 325°C, and then held 
for 5 min. Eluate from GC was analyzed under 70 eV electron ionization (EI) with full 
mass scan. The mass scan range measured was m/Z 50-550. The peak area of each 
metabolite standard relative to that of the added internal standard, etiocholanolone, was 
determined for selected ion retrieval chromatograms to establish a standard curve for 
quantitating DHEA metabolite formation. An internal standard curve was prepared for 
each compound of interest spanning the concentrations above and below those observed 
in the biological samples measured. 
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Statistical analysis. Experiments were conducted in triplicate and mean ± standard 
deviation (SD) was determined. Statistical significance was determined using a two-
tailed Student's t test withp ~ 0.05 as the criterion for significance. 
RESULTS 
Analysis of DHEA and its metabolites using GC/MS. Fitzpatrick et al. (2001) utilized 
LC/MS to separate and quantify DHEA and its resulting oxidative metabolites. DHEA 
was found to be converted by human liver microsomal fractions to 7a-OH-DHEA, 16a-
OH-DHEA and an unknown mono-hydroxylated compound. 7-oxo-DHEA was also 
observed iflonger incubation times were utilized (Fitzpatrick et at., 2001; Robinzon et 
at., 2003). This method was hindered by poor ionization efficiencies ofDHEA and its 
metabolites under conditions of chemical ionization at atmospheric pressure. For the 
current studies, the possibility of attaining better sensitivity and resolution ofDHEA and 
metabolites using GC/MS was examined. Therefore, a GC/MS method, utilizing 
derivatization, was developed to separate and quantitate known DHEA metabolites. 
DHEA and its metabolite standards contain keto and hydroxyl functional groups 
that can be derivatized to form stable and more ionizable molecules. In order to stabilize 
the compounds and improve their separation by GC, MOX was added to the commercial 
standards or samples to derivatize oxo functional groups (i.e. prevent keto-enol 
tautomerization) followed by the addition of BSTF A-TMS to derivatize hydroxyl groups 
(Figure 8A). The standards were then separated by GCIMS after conditions for baseline 
separation of all metabolites was achieved (Figure 8B). The identity of the compounds 
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Figure 8. Separation of DHEA and metabolites by GCIMS. A GCIMS method was developed for quantification ofDHEA 
metabolites in various species. (A) Schematic representation ofthe structure and derivatization ofDHEA. (B) Chromatogram of the 
separation ofDHEA and metabolites. (C) Electron ionization mass spectrum ofDHEA. 
TABLE IV 
GC-SIM-MS data for seven steroids. 
Selected Ion 
(m/Z)b Characteristic Ions (m/z) 
Steroid RT3 Ions quantified [M·t 
-
CH3 -CH3O -(CH3)3SiO aC bd Linearitye 
(-MOX) (-TMS) 
ADIONE 8.91 344,329 344 329 0.225 0.000461 0.912 
Etio 9.60 270,360 360 270 IS IS IS 
w 7a-OH-DHEA 9.68 387,356 356 387 0.722 0.0225 0.991 N 
DHEA 10.40 268,358 358 268 0.172 0.00965 0.985 
16a-OH-DHEA 10.54 446,356 446 356 0.112 0.0059 0.943 
7/3-0H-DHEA 10.79 387,477 477 387 0.468 0.00984 0.976 
7-oxo-DHEA 13.92 432,401 432 401 0.0124 0.0000345 0.935 
IS (internal standard) a Retention time in minutes. Dronsused for quantitative analysis are underlined. C a = Slope = relative mass 
response = mean peak area ratio of steroid X mass of IS/mass of steroid; b = y-intercept. d Linearity is represented by the linear 
correlation coefficients of the calibration curves for each standard. 
ionization mass spectra for each compound as shown for DHEA (Figure 8C). The 
retention times and MS data are shown in Table IV. Etiocholanolone, which has been 
previously shown not to be a direct metabolite ofDHEA under these conditions, was 
used as an internal standard. The peak areas of each standard relative to etiocholanolone 
were used to prepare a standard curve to quantify metabolite production. 
Quantification of DHEA and metabolites by GC/MS. In order to study the liver 
microsomal hydroxylation ofDHEA in various species, microsomal protein fractions (0.5 
mg/mL) from rat, hamster or pig were incubated with 50 ~MDHEA and an NADPH 
regenerating system consisting of sodium isocitrate, isocitrat¢ dehydrogenase and MgS04 
for up to 20 minutes. Extracts ofthe microsomal incubation mixtures were derivatized 
and then analyzed using GC/MS. In order to quantify and confirm metabolite identities, 
two or three characteristic ions for each steroid were selected on their basis of their mass 
fragmentation. The peak areas of the selected ions of each metabolite were obtained and 
compared to that of the internal standard, and the absolute values were calculated using 
calibration curves from the standards. 
Figure 9 shows a representative chromatogram of the total ion current for rat liver 
microsomal metabolism ofDHEA at 0 minutes. DHEA was metabolized by rat liver 
microsomes to 7a-OH-DHEA and 16a-OH-DHEA in 10 minutes as indicated by the 
presence of two metabolite peaks corresponding in retention times to the authentic 
compounds (Figure 10). Moreover, NADPH was required for microsomal metabolism of 
DHEA, since no metabolite peaks were formed in the absence of an NADPH 
regenerating system (data not shown). 
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Figure 9. Rat liver microsomal metabolism of DHEA at 0 minutes. Rats were fed 
control diet for 5 days and then liver microsomal fractions were isolated. Metabolic 
assays were performed in triplicate with 2 mL reaction mixtures containing microsomal 
protein (lmg/mL), NADPH regenerating system, and 50 /-lM DHEA incubated at 37°C 
for 10 minutes in a shaking water bath. Reactions were terminated at 0 minutes. Ethyl 



















9.12 DH EA 
16a.-OH 
10.59 
R eien.ue>n Tim e (JIlin.) 
15 .00 
Figure 10. Rat liver microsomal metabolism ofDHEA at 10 minutes. Rats were fed 
control diet for 5 days and then liver microsomal fractions were isolated. Metabolic 
assays were performed in triplicate with 2 mL reaction mixtures containing microsomal 
protein (lmg/mL), NADPH regenerating system, and 50 flM DHEA incubated at 37°C 
for 10 minutes in a shaking water bath. Reactions were terminated at 10 minutes. Ethyl 
acetate extracts were examined by GC/MS. 
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Rat, hamster, pig and human liver microsomal fractions all metabolized DHEA. 
DHEA was rapidly metabolized in rat (7.2 nmollminlmg) and hamster (18.9 
nmollminlmg). Rat liver micro somes produced two major monohydroxylated 
metabolites, 7a-OH-DHEA (4.6 nmollminlmg) and 16a-OH-DHEA (2.6 nmol/minlmg). 
In the hamster, DHEA was converted to 7a-OH-DHEA (7.4 nmol/minlmg) and 16a-OH-
DHEA (0.26 nmollminlmg), as well as 11 unidentified metabolites that accounted for a 
rate ofDHEA conversion of 11.2 nmol/min./mg. Pig microsomal metabolism ofDHEA 
displayed lower rates of conversion than rat and hamster metabolism and produced three 
metabolites, 7a-OH-DHEA (0.70 nmollmin./mg), 16a-OH-DHEA (0.16 nmollmin.lmg) 
and ADIONE (0.26 nmol/min.lmg). Although ADIONE has been shown to be formed in 
the cytosolic fractions of other species with NAD+, the formation of ADIONE by pig 
liver microsomal fractions required NADPH, but not NAD+ or NADP+ (data not shown), 
indicating the presence of a 3p-hydroxysteroid dehydrogenase enzyme activity in not 
only cytosolic fractions, but also anabolic liver microsomal fractions of the pig (Figure 11 
& Table V). Future studies will evaluate the role of CYPs in this reaction. 
Upon incubation with 50 !J.M DHEA, one human liver microsomal fraction 
(HL110) hydroxylated DHEA at a rate of7.8 nmollminlmg. Like rat, hamster, and pig, 
7a-OH-DHEA (0.66 nmollminlmg) and 16a-OH-DHEA (3.6 nmol/minlmg) were 
produced (Figure 12 & Table V). Unlike the other species, the human also converted 
DHEA to 7P-OH-DHEA at a significant rate (3.5 nmollminlmg). The identity of the 
unique metabolite, 7p-OH-DHEA, was established based on its GC retention time and a 
mass spectrum identical (Figure 13) to 7P-OH-DHEA standard (Figure 14), but distinct 
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Figure 11. Time dependent formation of DHEA metabolites by rat, hamster and pig 
after GC/MS analysis. (A) DHEA metabolite fonnation from rat liver microsomes. (B) 
DHEA metabolite fonnation from hamster liver microsomes. (C) DHEA metabolite 
fonnation from pig liver microsomes. (e: DHEA; 0: 7a-OH-DHEA; .... : 16a-OH-
DHEA; .: ADIONE). The results are expressed as the average of triplicate experiments 
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Total metabolite fonnation was based on amount ofDHEA (50 J-lM) converted to products during the linear phase of reaction. Known 
metabolites were quantified by measuring the peak area and comparing to known standards nonnalized to the internal standard 
etiocholanolone. The results are expressed as the average of triplicate experiments of at least two reactions in which the SD varied by 
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Figure 12. Time dependent formation of DHEA metabolites by human liver 
microsomal fractions. DHEA metabolite formation from liver microsomes of human 
subject 110. (e: DHEA; 0: 7a-OH-DHEA;.: 16a-OH-DHEA; 0: 7~-OH-DHEA). 
The results are expressed as the average of triplicate experiments of at least two reactions 
in which the SD varied by s: 5%. 
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Figure 13. Characteristic mass spectrum of 7~-OH-DHEA from human microsomal 
fractions. Electron ionization mass spectra of7~-OH-DHEA from human (110) liver 
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Figure 14. Characteristic mass spectrum of 7~-OH-DHEA standard. Electron 
ionization mass spectra of7~-OH DHEA standard (inset: 20X 477 mass spectrum). 
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all human microsomal fractions tested oxidized DHEA as well as sample HLII0. In fact, 
although fO).lr other human liver microsomal fractions displayed the same metabolite 
profile as HLII0, the other human fractions metabolized less than 2 nmol/minlmg of 
DHEA in 10 minutes (Figure 15), indicating inter-individual variability ofDHEA 
metabolism of the human samples that were measured. 
Cytochrome P450 metabolism of DHEA. To establish which cytochrome P450 was 
responsible for DHEA metabolite production, 50 IlM DHEA was incubated with 
membrane fractions from baculovirus-infected insect cells that express both a specific 
P450 and its flavoprotein oxidoreductase, NADPH:cytochrome P450 oxidoreductase. 
CYP3A4 and CYP3A5 apparently are responsible for the production of7a-OH-DHEA, 
16a-OH-DHEA and 7~-OH-DHEA, with CYP3A4 exhibiting the highest rate of product 
formation. CYP3A 7 is not expressed in adult liver, but is expressed in fetal liver 
(Hakkola et at., 1994); it also formed 7~-OH-DHEA, but no detectable 7a- or 16a-OH-
DHEA (Table IV). CYP2Dl was the rat P450 that most extensively converts DHEA to 
16a-OH-DHEA. CYP2Bl and CYP2Cli also contributed to 16a-OH-DHEA metabolite 
production, while CYP3A23 was the rat P450 apparently responsible for 7a-OH-DHEA 
formation. 
DISCUSSION 
Many animal studies have suggested beneficial effects of DHEA administration in 
pharmacological dosages. Exogenous DHEA administration to humans has also been 
suggested to likely also have beneficial effects in cancer prevention, immune function, 
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Figure 15. Time dependent formation ofDHEA metabolites by human liver 
microsomal fractions. Liver microsomal metabolism from 4 human samples. Ce : 
DHEA; 0: 7a-OH-DHEA;~: 16a-OH-DHEA; 0: 7~-OH-DHEA). The results are 
expressed as the average of triplicate experiments of at least two reactions in which the 
SD varied by ::: 5%. 
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TABLE VI 
Rates of DHEA metabolites formed from baculovirus expressed P450 
Rate of Fonnation (nmol/minlnmol P450) 
7a-OHDHEA 7P-OHDHEA 16a-OHDHEA 
10 min. 10 min. 10 min. 
Human CYPs 
3A4 0.50** 1.4** 1.0** 
3A5 0.50** 0.75* 0.25* 
3A7 ND 0.75* ND 
2A6 ND ND ND 
2B6 ND ND ND 
2C8 ND ND ND 
2C9 ND ND ND 
2C19 ND ND ND 
2D6 ND ND ND 
Rat CYPs 
3A23 1.0* ND ND 
2Bl ND ND 0.63* 
2Cll ND ND 1.9** 
2C12 ND ND ND 
2C13 ND ND ND 
2D1 ND ND 2.9* 
Metabolic assays were perfonned in triplicate in 2 mL reactions mixtures containing CYP 
baculovirus (~0.4 nmol/mL), NADPH regenerating system, and 50 flM DHEA and 
incubated at 37°C for 10 minutes in a shaking water bath. Reactions were tenninated at 5 
minutes and 10 minutes. Ethyl acetate extracts were examined by GC/MS. The results 
are expressed as the average of triplicate experiments of at least two reactions in which 
the SD varied by:s 5%. The rates of metabolism during the linear portion of the reaction 
are statistically different from a reaction in the absence ofbaculovirus preparation 
(*p<0.05 or **p<O.Ol). ND, not detected since the rate of product conversion was less 
than 0.05 nmol/mininM P450. 
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diabetes, obesity and cardiovascular disease (Kroboth et at., 1999). Since DHEA is 
considered a natural product/dietary supplement and is available as an over the counter 
supplement, the mechanism of action of this sterol and its metabolites become important 
to study. 
DHEA is metabolized to androgens and estrogens in steroidogenic tissues; 
however, the metabolism ofDHEA in other tissues has not been extensively studied. 
Fitzpatrick et at. (2001) utilized LC/MS to identify the metabolites formed by the 
transformation ofDHEA by rodent and human liver microsomal fractions. 16a-OH-
DHEA, 7a-OH-DHEA and 7-oxo-DHEA were identified in both species. However, the 
major metabolite produced in humans was a mono-hydroxylated DHEA metabolite 
whose position of hydroxylation was unknown. Additionally, Fitzpatrick et at. (2001) 
demonstrated that formation of these products was inhibited by miconazole indicating the 
role of cytochrome P450s in the metabolism ofDHEA. With human liver microsomal 
fractions, the high levels of DHEA hydroxylation was shown to be due to CYP3A, since 
its metabolism to several products was strikingly inhibited by troleandomycin (approx. 
80% inhibition), while the inhibitor was less effective in inhibiting DHEA hydroxylation 
in rat liver microsomal fractions (approx. 20% inhibition). Our results demonstrate that 
human liver microsomal hydroxylation ofDHEA is predominantly due to the role of 
CYP3A, while in rat other CYPs account for significant conversion to 16a-OH-DHEA 
(CYP2Bl, 2Cll, 2Dl, and others). In addition, a-napthoflavone (inhibitor ofCYP1) and 
quinidine (inhibitor of CYP2D) also slightly inhibited DHEA hydroxylation by rat liver 
microsomes (Fitzpatrick et al., 2001) demonstrating that several rat CYPs are involved in 
DHEA hydroxylation. We have also shown that DHEA and its cytosolic metabolites 
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induce CYP3A23 (native gene in rat hepatocytes and reporter gene constructs in HepG2 
cells) demonstrating that DHEA can induce its own metabolism to the 7a-OH-DHEA by 
induction of CYP3A through action of the pregnane X receptor in rats (Ripp et aI., 2002). 
This increase in 7a-hydroxylase over 16a-hydroxylase activity is also due to the negative 
regulation ofCYP2Cll, a 16a-hydroxylase, by DHEA (Ripp et al., 2003), demonstrating 
a complex metabolic scheme when contrasting metabolism across species. The purpose 
of the current study was to further identify the unknown metabolite formed by the human 
liver microsomal metabolism ofDHEA and identify the specific P450s responsible for 
production of various DHEA metabolites. 
Although LC/MS allowed for the identification of most of the DHEA metabolites, 
quantification ofDHEA metabolism was difficult to attain due to low ionization 
efficiency of metabolites under conditions of chemical ionization at atmospheric pressure 
(Fitzpatrick et al. 2001). The current study, a GC/MS method was developed to provide a 
more sensitive method for identification and quantification of the liver microsomal 
metabolism of DHEA. 
The current study examined the oxidative metabolism ofDHEA by rodent, 
hamster, pig and human microsomal fractions. Each species extensively converted 
DHEA into mono-hydroxylated metabolites. ADIONE was also produced in pig liver 
microsomal fractions in the presence ofNADPH and oxygen. AD lONE is an anabolic 
steroid that mimics the effects of testosterone to increase growth and development of 
muscle tissue. Since it has been reported to promote lean muscle growth, AD lONE is 
used frequently by athletes interested in increasing muscle mass (Ziegenfuss et al., 2002). 
3~-hydroxysteroid dehydrogenases convert DHEA to ADIONE in the presence ofNAD. 
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Pigs are primarily raised for lean muscle production, suggesting a possible role for 
enhanced levels of an NADPH-dependent microsomal 3~-hydroxysteroid-dehydrogenase 
activity in pig liver. Hamster liver microsomal fractions also converted DHEA into 70.-
OH-DHEA and 16a-OH-DHEA, as well as 11 unidentified hydroxylated DHEA species 
that are possibly secondary metabolites. These results suggest that several cytochrome 
P450 enzymes may playa role in the DHEA metabolism in the hamster and demonstrate 
the significant species differences in the metabolism ofDHEA. 
Metabolism ofDHEA by human microsomal fractions yielded both 7a-OH-
DHEA and 16a-OH-DHEA; however, the human was the only species to produce 7~­
hydroxy-DHEA. Fitzpatrick et al. (2001) previously reported that human liver 
microsomal metabolism ofDHEA resulted in the production of7a-OH-DHEA, 16a-OH-
DHEA, 7-oxo-DHEA and an unknown monohydroxylated DHEA accounting for nearly 
half of total metabolite production. The current study identified 7a-OH-DHEA and 160.-
OH-DHEA production, as well as 7~-OH-DHEA which accounts for approximately 44% 
of total metabolite production. This mono-hydroxylated species, namely 7~-OH-DHEA, 
is likely the unknown compound previously reported by Fitzpatrick et al. (2001) and was 
recently shown to be formed by Stevens et al. (2003) to be formed by CYP3A4 and 3A5. 
Not all human microsomal fractions exhibited extensive oxidative metabolism ofDHEA. 
Although one human microsomal fraction (HLll 0), previously noted by Guengerich and 
coworkers to contain high levels ofCYP3A (Guengerich et al., 1991), metabolized 
DHEA at a high rate (7.8 nmol/minlmg), fractions from four other humans hydroxylated 
DHEA at much lower rates (::: 2 nmol/minlmg ofDHEA). Although not all human 
microsomal fractions formed hydroxylated metabolites at the same rate, all human 
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microsomal fractions exhibited similar metabolite profiles. The various rates in DHEA 
metabolism among humans could be attributed to differences in CYP expression or 
various CYP polymorphisms. 
Although 7a-, 16a- and 7P-OH-DHEA were produced in human liver 
microsomal fractions, 7-oxo-DHEA was also formed, albeit at later time points 
(Fitzpatrick et al., 2001). Additionally, we have found that upon treatment with 50 f.lM 
of7-oxo-DHEA, human liver fractions can convert 7-oxo-DHEA into 7a- and 7P-OH-
DHEA indicating a complex metabolic pathway for DHEA in the liver that includes 11 p-
hydroxysteroid dehydrogenase activity (Robinzon et al., 2003). 
The human CYP3A family plays a dominant role in the metabolic elimination of 
more drugs than any other biotransformation enzyme (Lamb a et al., 2002). Fitzpatrick et 
al. (2001) reported that selective P4503A inhibitors were able to inhibit DHEA 
metabolite production in the human. The current study utilized insect cells infected with 
baculovirus expression vectors to examine the CYPs responsible for the liver microsomal 
metabolism ofDHEA. Recombinant CYP3A4 was responsible for the majority of the 
conversion ofDHEA into 7a-OH-DHEA, 16a-OH-DHEA and 7P-OH-DHEA. CYP3A5 
also converted DHEA into the same metabolites; however, the hepatic fetal enzyme, 
CYP3A7 was found to only hydroxylated DHEA to 7P-OH-DHEA. The rat CYP2Dl 
converted DHEA to 16a-OH-DHEA as did CYP2Cll and CYP2Bl. Additionally, 
CYP3A23, a major constitutive P450 in rat liver, was the CYP responsible for 7a-OH-
DHEA production in the rat. This pattern of hydroxylation is strikingly different from 
the human CYP3A4 or 3A5. 
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I The current study utilized recombinant P450 expressed in insect cells to examine 
! 
DHEA metabolism. The assay of purified P450s requires that they be reconstituted with 
NADPH:cytochrome P450 reductase in a complex mixture which includes detergent, 
phospholipids and reduced glutathione (Gillam et al., 1995). Some in vitro reconstitution 
experiments have shown that for a number ofP450s, the inclusion of cytochrome b5 can 
significantly increase substrate turnover by monooxyenase system by improving the 
coupling between the P450 and NADPH cytochrome P450 reductase (Holmans et al., 
1994; Gorsky and Coon., 1986; Bell and Guengerich, 1997). Cytochrome bs is a heme 
protein whose mechanism of action in reconstituted systems is not clear. It has been 
suggeSted that cytochrome bs plays a role in donating electrons from 
NADPH:cytochrome P450 oxidoreductase to CYP (Bell and Guengerich., 1997; 
Yamazaki et al., 1996; Morgan and Coon, 1984). Although the authors' acknowledge 
there is evidence that the inclusion of cytochrome bs in bacterial membranes may 
enhance CYP3A4 activity, inclusion of this cytochrome b5 did not enhance DHEA 
metabolism by recombinant CYP3A4 under the conditions of our assay (K.K. Michael 
Miller and R.A. Prough, unpublished data). 
In conclusion, this study demonstrates that different species exhibit unique DHEA 
metabolite profiles due to the stereospecificity of hydroxylation by the various CYPs that 
metabolize DHEA. The unknown major metabolite produced by the human previously 
reported by Fitzpatrick et al. (2001) was shown to be 7~-OH-DHEA. DHEA and some 
of its metabolites are known to interact with certain nuclear receptors and activate CYP 
transcription. This could explain the mechanism of some beneficial effects that have 
been reported with the administration ofDHEA. 
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CHAPTER III 
DHEA AND ITS METABOLITES ACTIVATE ESTROGEN RECEPTOR 
INTRODUCTION 
The estrogen receptor (ER) is a ligand-activated transcription factor and a 
member of the steroid hormone nuclear receptor superfamily. The two subtypes ofER, 
ERa and ER~, mediate the physiological effects of its primary ligand, 17~-estradiol (E2) 
within various tissues (Nillson and Gustafsson, 2002). Binding of ER to an estrogenic 
ligand induces a conformational change that results in activation ofER and binding of the 
receptor to specific DNA sequences known as estrogen responsive elements (EREs) 
(Klinge, 2001). Association with DNA initiates transcription, thereby regulating the 
activation or repression of ER target genes (Parker et aI., 1993). 
Estrogens are predominantly synthesized in the ovary and are responsible for 
cellular growth and differentiation, required for puberty and reproductive processes, as 
well as maintaining bone density and cholesterol levels. Additionally, estrogen is 
essential for growth and development of the mammary gland, and therefore has been 
associated with the promotion and growth of breast cancer (Clark et al., 1992). 
Since estrogens are mitogens in approximately one-third of breast tumors, specific 
estrogen antagonists have been developed for the treatment of hormone-dependent breast 
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cancer. (Jordan and Murphy, 1990). Tamoxifen is one of the most widely used 
antiestrogens that inhibits transcriptional activation by the receptor (Berry et al., 1990). 
Although tamoxifen serves to stop tumors from proliferating, it also exhibits partial 
agonist activity (Jordan, 1984). Therefore, the antiestrogen compound ICI 182,780 was 
developed which does not exhibit agonist activity. The ICI compound is a derivative of 
E2, but contains an alklamide functional group in the 7a position of the sterol nucleus 
(Bowler et aI., 1989) (Figure 16). ICI 182,780 binding to ERa results in a conformation 
of the receptor which is different than that formed with known agonists of the receptor 
(Pike ot aI., 2001). Further ICI 182,780 reduces steady-state levels of ERa by increasing 
the turnover of the protein in the nucleus by targeting ER to the 26S proteosome (Reese 
and Katzenellenbogen, 1992 and Wijayaratne et aI., 1999). In addition to tamoxifen and 
ICI 182,780, aromatase inhibitors are a family of hormonal treatments that have shown 
significant activity against breast cancer in post-menopausal woman with estrogen-
sensitive tumors (Lonning, 1998). Aromatase, CYP 19 (Figure 1), is expressed in breast 
cancer tissue and catalyzes the conversion of C 19 steroids to estrogens. Therefore, 
aromatase inhibitors reduce the amount of circulating estrogen and thereby inhibit the 
growth of estrogen sensitive tumors (Geisler et ai., 1996). 
DHEA and its sulfate, DHEA-S, are estrogen precursors whose role in the 
progression of breast cancer has yet to be clearly defined. Plasma levels ofDHEA-S are 
higher than that of other sterols secreted by the adrenal gland (Ebeling and Koivisto, 
1994). The blood plasma levels ofDHEA-S are maximal in the middle of the second 





Figure 16. Structure of estradiol and common anti-estrogenic compounds. 
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been suggested to have many beneficial effects during this state of decline in DHEA 
fonnation. In fact, DHEA has been reported to have anti-carcinogenic effects in the 
mammary gland of rodents after chemical induction (Feo et al., 2000). However, a role 
ofDHEA in human breast cancer has been debated for years. For instance, DHEA has 
been reported to be present in nonnal tissue as well as breast tumors (Brignardell et aI., 
1995 and Massobrio et al., 1994). Although DHEA has been suggested to have a 
protective effect in pre-menopausal women, a positive correlation was observed between 
DHEA plasma levels and breast cancer risk in postmenopausal women (Adams, 1998 
and Gordon et aI., 1990). Also, it has been reported that DHEA-S levels >90 ~g/dL pose 
a potential risk factor for breast cancer progression in patients treated with tamoxifen 
(Calhoun et al., 2003). Maggiolini et al. (1999) reported that DHEA and ADIOL directly 
activated transfected ERa reporter genes and stimulated proliferation ofMCF-7 cells, an 
ERa-dependent human breast cancer cell line, as well as, MCF-7SH cells, an estrogen-
independent MCF-7 variant. Moreover, Mizokami et al. (2004) reported that ADIOL is a 
major DHEA metabolite fonned in human prostate tissue and that ADIOL levels are 
appreciable in prostate cancer tissue after honnone therapy. 
Therefore, the possibility that DHEA and its metabolites activate ER is critical for 
understanding the biological events of estrogen-mediated gene regulation in nonnal and 
diseased tissues. In this study, DHEA and its metabolites were tested to for their ability 
to activate human ERa and ERP in in vitro assays. 
MATERIALS AND METHODS 
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Chemicals. Androstenediol, androstenedione, etiocholanolone, DHEA, DHEA-sulfate, 
7a-hydroxy-DHEA, 7p-hydroxy-DHEA, 7-oxo-DHEA 11P-hydroxy-DHEA, 16a-
hydroxy-DHEA, and estradiol were purchased from Steraloids, Inc. (Wilton, NH). ICI 
182,780 and 4-hydroxytamoxifen (4-0HT) were purchased from Tocris, Inc. (Ellisville, 
MO). Miconazole was purchased from Sigma (St. Louis, MO) and exemestane was a 
generous gift from Pharmacia Upjohn Corp., Kalamazoo, MI. RRTHC, a selective ERP 
antagonist/ERa agonist was a generous gift from Dr. John A Katzenellenbogen of the 
University of Illinois (Sun et aI., 1999) 
Plasmi4s. The pCMV expression plasmid containing the cDNA for human ERa (Reece 
and Katzenellenbogen, 1991) was a gift from Dr. Benita Katzenellenbogen (University of 
Illinois at Urbana). The pSG5 expression plasmid containing the cDNA for human ERP 
(hERP 1, 530 aa) was a gift from Dr. Eva Enmark (Karolinska Hospital, Stockholm, 
Sweden). The reporter plasmid ERELUC was constructed by inserting three copies of a 
consensus oligonucleotide containing the ERE into the KpniiSacI site of a pGL3 
promoter linked to the firefly luciferase reporter gene (Klinge, 1999). The expression 
plasmid for p-galactosidase (pCMVP) was purchased from CLONTECH (Palo Alto, 
CA). All plasmids were transformed into DH5a Escherichia coli bacteria, isolated, and 
prepared for use in transient transfections using QIAGEN plasmid prep kits (QIAGEN, 
Chatsworth, CA). 
Transient Transfections. HEK293, HepG2, CHO-Kl and MDA-MB-231 cells (ATCC) 
were grown at 37°C in 5% carbon dioxide atmosphere. Cells were plated at 1.5 X 105 
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cells/well in 12-well plates containing minimal essential medium supplemented with 5% 
charcoal-stripped fetal bovine serum. Twenty-four hours after plating, cells were 
transfected using 4 ~g/ml LipofectAMINE (Invitrogen, Carlsbad, CA) with hERa or 
hER~ expression plasmid (150 nglml), ERELUC reporter plasmid (250 nglml), and ~­
galactosidease expression plasmid in serum free medium. Each well was overlaid with 1 
ml oftransfection mixture and incubated overnight. After removal of the transfection 
mixture, cells were supplemented with 5% charcoal-stripped serum. Transfected cells 
were treated with 500X concentrated stocks ofDHEA and metabolites in ethanol, and 
harvested 24 h later with 1 00 ~l of cell lysis buffer (Prom ega, Madison, WI). ~­
Galactosidase and luciferase activities were detennined as described by Falkner et al. 
(1998). The data are expressed as luciferase activity relative to ~-galactosidase activity 
to correct for transfection efficiency. All transient transfection experiments were 
perfonned in triplicate or quadruplicate, and experiments were repeated at least twice to 
confinn results. 
Estradiol Ligand Binding Assay. Purified recombinant human ERa or ER~ were 
purchased from Panvera (Madison, WI) were incubated in a final volume of 54 ~L in 
TDPK111 buffer (40 nM Tris-HCI (pH 7.5), 1 mM DTT, 0.5 mM PMSF, 111 mM KCI) 
containing 30 nM eH]-E2 (2,3,4,7,-eH](N)17~-estradiol, 74 Ci/mmol, NET-317, NEN) 
for one hour at 37°C prior addition of a 10% hydroxyapatite (HAP) solution in TDPK111 
(Pavlik and Coulson, 1976). HAP was added and incubated for 30 minutes. The 
supernatant was discarded and the pellet was resuspended in TDPK11 buffer and washed 
two times. After the final wash, the pellet was resuspended in scintillation fluid for 
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determination of eH]E2. Eight reactions were performed for each concentration, four 
"cold" reactions and four "hot" reactions. "Cold" reactions contained increasing molar 
amounts ofE2, DHEA, DHEA-S, ADIOL, ADIONE, and 7-oxo-DHEA as a competitor 
for ER binding with eH]E2• Ethanol was added in an equal volume to the "hot" reactions 
containing ER and [3H]E2. The percent of binding of the test compounds to ER was 
calculated by first subtracting the nonspecific binding to provide the specifically bound 
ligand. The value on the Y axes is expressed as the percentage of eH]E2 bound. 
Statistical Analysis. Experiments were conducted in triplicate or quadruplicate and 
means ± standard deviations were determined. Statistical comparisons among treatment 
groups were determined using a two-tailed Student's t test, with p < 0.05 as the criterion 
for significance. 
RESULTS 
The ability of DHEA and metabolites to activate gene transcription through ERa and 
ERP was tested in cell-based reporter gene assays. HEK293 (human embryonic kidney) 
and HepG2 (human hepatoma) cell lines were transiently transfected with luciferase 
reporter constructs containing a luciferase reporter plasmid constructed by using three 
copies of a consensus ERE containing oligomer. Cells were also cotransfected with 
expression plasmids for either human ERa or ERP and treated with 17p-estradiol, DHEA 
or its metabolites. Because the expression ofERELUC is induced through ligand-
mediated activation of the nuclear receptors ERa and ERP, the ability of 17p-estradiol to 
activate gene transcription through ERa and ERP was tested in a number of cell lines 
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including HEK293, HepG2, CHO-Kl (Chinese hamster ovary), and MDA-MB-231 cells. 
In our hands, ERa displayed a high basal activity in HepG2 cells, but had a limited 
response to 17~-estradiol. In contrast, ER~ was not active in regulating ERELUC 
expression in HEK293 cells and most other cells, but was ligand-activated in HepG2 
cells. As shown in Figure 17, both cell lines tested supported activation of the ERELUC 
reporter in response to the known ERa and ER~ agonist, 17~-estradiol, but ERa was 
maximally responsive in HEK293 cells, while ER~ was maximally responsive in HepG2 
cells. It was noted that the response ofER~ in HepG2 cells was increased nearly 8-fold 
by 17~-estradiol, while ERa was maximally increased 3-4 fold in response to 17~­
estradiol in HEK293 cells. 
Subsequently, 5 ).lM ofDHEA and many of its known metabolites (Miller et ai., 
2004) were tested for their ability to induce expression ofERELUC in the presence of 
ERa in HEK293 cells or in the presence ofER~ in HepG2 cells, respectively (Figure 18). 
As a control, an empty expression vector was cotransfected with ERELUC and after 
treatment with DHEA or its metabolites, there was no additional induction of ERELUC 
over vehicle in either HEK293 cells or HepG2 cells, indicating that both cell types were a 
viable null cell-based assay to test ER activation. Although the induction of the 
expression of ERELUC via ER~ was more robust in HepG2 cells than the induction of 
ERELUC via ERa in HEK293 cells, DHEA, DHEA-S, and ADIOL significantly induced 
the expression ERELUC via human ERa in HEK293 cells. While 11 ~-hydroxy- DHEA, 
7~-hydroxy-DHEA, 7a-hydroxy-DHEA, 16a-hydroxy-DHEA, and ETIO exhibited 
modest activation of the ER~, the cytosolic metabolites AD lONE and ADIOL as well as 
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Figure 17. 17~-Estradiol increases expression of 3EREc38-dependent reporter gene 
activity. HEK 293 cells were transfected with ERELUC reporter plasmid and expression 
vector for human ERa and HepG2 cells were transfected with ERELUC reporter plasmid 
and an expression vector for human ER~. Both cells types were treated for 24 h with 
17~-estradiol. The cells were harvested and the lysates were assayed for ~-galactosidase 
and luciferase activities. Data represent the mean ± S.D. of three wells. Experiments 
were repeated three times with similar results. Statistical significance was determined 
using analysis of variance followed by Student's t tests. * significantly different from 
cells treated with vehicle, p<O.05, ** p<O.Ol. 
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metabolites. HEK293 and HepG2 cells were transfected with ERELUC reporter plasmid 
and expression vector for human ERa or human ER~ respectively. Both sets of cells 
were treated for 24h with vehicle or 5 ~M ofDHEA or its metabolites. Cells were then 
harvested and lysates assayed for ~-galactosidase and luciferase activities. Data represent 
the mean ± S.D. of three wells. Experiments were repeated three times with similar 
results. Statistical significance was determined using analysis of variance followed by 
Student's t tests. *, significantly different from cells treated with vehicle, p < 0.05, **, 
p<O.OI. Metabolites tested: 17~-estradiol (E2) DHEA, DHEA-sulfate (DHEA-S) 11~-
hydroxy-DHEA (11~-OH-DHEA), 7~-hydroxy-DHEA (7~-OH-DHEA), 7a-hydroxy-
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DHEA (7a-OH-DHEA), 16a-hydroxy- expression ofERELUC via ER~ was more robust 
in HepG2 cells than the induction ofERELUC via ERa in HEK293 cells, DHEA, 
DHEA-S, and ADIOL significantly induced DHEA (16a-OH-DHEA), 7-oxo-DHEA, 
androstenediol, androstenedione and etiocholanolone. 
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cells. Due to the difference in induction ofERELUC expression in the different cell 
lines, Figure 19 shows the induction of luciferase expression through ERELUC by 
DHEA metabolites normalized to 17p-estradiol. Concentration-response studies were 
conducted to evaluate the potency of ERa and ERP mediated induction of ERELUC by 
DHEA and metabolites (Figure 20 and Figure 21). ADIOL was the most potent inducer 
ofERELUC, inducing expression by nearly 3-fold with ERa, while DHEA and DHEA-S 
induced ERELUC expression approximately 2-fold with ERa. With ERP, ADIONE was 
the most potent inducer, inducing expression of ERELUC by approximately 10-to 12-
fold. 7-oxo-DHEA, DHEA, and ADIOL also induced expression ofERELUC by 
approximately 6- to 8-fold with ERp. This response of different sterols in maximal 
activation is reminiscent of the differences seen between the rodent vs. the human 
pregnane X receptor (PXR), where pregnenolone 16a-carbonitrile activates the rodent 
receptor, but not the human receptor (Jones et aI., 2000). In contrast, rifampacin 
activates the human pregnane X receptor, but not the murine receptor. 
The ER is a member of the nuclear receptor superfamily that acts as a ligand-
dependent transcription factor. Upon ligand binding, the receptor binds to the response 
elements of the target genes to activate transcription. Since estrogens are mitogens in 
approximately one-third of breast tumors (McGuire, 1976), specific estrogen antagonists 
have been developed for the treatment of hormone-dependent breast cancer. The non-
steroidal compound, tamoxifen is one of the most widely used antiestrogens (Jordan, 
1984). Tamoxifen binds with high affinity to ER (Katzenellenbogen et al." 1983), but 
inhibits transcriptional reporter activity by DHEA and metabolites when the cells were 
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Figure 19. Normalized ERELUC reporter activity in response to DHEA and 
metabolites. HEK293 and HepG2 cells were transfected with ERELUC reporter plasmid 
and expression vector for human ERa or human ER~ respectively. Both sets of cells 
were treated for 24 h with vehicle or 5flM DHEA metabolites. Cells were then harvested 
and lysates assayed for ~-galactosidase and luciferase activities. Data are normalized to 
the optimal E2 concentration which was set to 1. Data represent the mean ± S.D. of three 
wells. Experiments were repeated three times with similar results. Metabolites tested: 
DHEA, DHEA-sulfate (DHEA-S) 11 ~-hydroxy-DHEA (11 ~-OH-DHEA), 7~-hydroxy-
DHEA (7~-OH-DHEA), 7a-hydroxy-DHEA (7a-OH-DHEA), 16a-hydroxy-DHEA 
(16a-OH-DHEA), 7-oxo-DHEA, androstendiol, androstenedione and etiocholanolone. 
Statistical significance was determined using analysis of variance followed by Student's t 
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Figure 20. Concentration-dependent activation of ERa. by I>HEA, I>HEA-S, and 
ADIOL in HEK293 cells. HEK293 cells were transfected with ERELUC reporter 
plasmid and expression vector for human ERa.. Cells were treated for 24h with varying 
concentrations ofE2, DHEA, DHEA-S, and ADIOL. Cells were harvested and lysates 
were assayed for ~-galactosidase and luciferase activities. The data represent the mean ± 
S.D. of three wells. Experiments were repeated at least twice with similar results. 
Statistical significance was determined using analysis of variance followed by Student's t 
tests. *, significantly different from vehicle-treated cells,p < 0.05, **,p<O.Ol. +, E2; ., 
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Figure 21. Concentration-dependent activation of ER~ by DHEA, 7-oxo-DHEA, 
ADIOL, and ADIONE in HepG2 cells. HepG2 cells were transfected with ERELUC 
reporter plasmid and expression vector for human ER~. The cells were treated for 24h 
with varying concentrations of E2, DHEA, 7-oxo-DHEA, ADIOL, and ADIONE. Cells 
were harvested and lysates were assayed for ~-galactosidase and luciferase activities. 
Data represent the mean ± S.D. of three wells. Experiments were repeated at least twice 
with similar results. Statistical significance was determined using analysis of variance 
followed by Student's t tests. *, significantly different from vehicle-treated cells, p < 
0.05, **,p<O.Ol. +, E2; ., DHEA; £., 7-oxo-DHEA; ., ADIOL; 0, ADIONE. 
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treated with 5 !J.M DHEA metabolites in combination with 100 nM: 4- hydroxytamoxifen 
(4-0HT), 1 !J.M ICI 182,780 (ICI), 1 !J.M R,R,-THC and 50 nM 17~-estradiol (E2) in the 
presence of cotransfected ERa or ER~ (Figure 22 and Figure 23)"The ER inhibitor, ICI 
182,780 as well as the ER antagonist, 4-hydroxytamoxifen inhibited the ERa-mediated 
induction of ERE by 17~-estradiol, DHEA, DHEA-S, and ADIOL and also the ER~ 
mediated induction of ERE driven reporter activity by 17~-estradiol, DHEA, 7-oxo-
DHEA, ADIOL, and ADIONE. The ERa agonist/ER~ antagonist R,R,-THC 
significantly inhibited the ER~ mediated induction ofluciferase activity by 17~-estradiol, 
DHEA, 7-oxo-DHEA, ADIOL, and ADIONE, but did not inhibit ERE activation 
mediated by ERa.In addition, 17~-estradiol did not act synergistically with DHEA 
metabolites in ERa- or ER~-mediated induction ofERELUC. 
Androgens are converted to estrogens by the aromatase enzyme complex, which 
consists of the Ubiquitous non-specific flavoprotein, NADPH-cytochrome P450 
reductase, and a specific microsomal form of cytochrome P450. A majority of breast 
cancers are estrogen sensitive, because they require the presence of estrogen in order to 
proliferate (Brodie et al., 1990). Aromatase inhibitors have recently been shown to have 
significantly greater activity against breast cancer in post-menopausal women with 
estrogen-sensitive tumors compared to tamoxifen (Smith, 2003). Their mode of action 
is in preventing the conversion of androgen precursors into active estrogens. In order to 
examine whether the ERa and ER~ ligand-mediated activation of ERELUC is mediated 
by direct ligand activation ofDHEA metabolites, cells were pretreated with 5 !J.M 
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Figure 22. Inhibition of ERELUC reporter activity in the pf(~sence of cotransfected 
ERa in HEK293 cells. HEK293 cells were transfected with an ERELUC reporter 
plasmid and an expression vector for human ERa. Cells were treated for 24 h with 5 ~M 
DHEA metabolite, 1 ~M 182,780 ICI, 100 nM 4-hydroxytamoxifen (4-0HT), 1 ~M 
R,R,-THC, or 50 nM 17~-estradiol (E2). Cells were then harvested and lysates assayed 
for ~-galactosidase and luciferase activities. Data represent the mean ± S.D. of three 
wells. Experiments were repeated three times with similar results. Statistical 
significance was determined using analysis of variance followed by Student's t tests. *, 
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Figure 23. Inhibition of EREL UC reporter activity in the presence of cotransfected 
ERP in HepG2 cells. HepG2 cells were transfected with ERELUC reporter plasmid and 
expression vector for human ERp. Cells were treated for 24 h with 5 IlM DHEA 
metabolite, 1 IlM 182,780 ICI, 100 nM 4-hydroxytamoxifen (4-0HT), 1 IlM R,R,-THC, 
or 50 nM 17p-estradiol (E2). Cells were harvested and lysates assayed for p-
galactosidase and luciferase activities. Data represent the mean ± S.D. of three wells. 
Experiments were repeated three times with similar results. Statistical significance was 
determined using analysis of variance followed by Student's t tests. *, significantly 
different from treated cells,p < 0.05 or **p , 0.01. 
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As shown by Figure 24, cells treated with miconazole and exemestane exhibited a 
slight although insignificant decrease in ERELUC reporter activity in response to DHEA 
and metabolites in the presence of ERa. However, the same decrease was seen with E2. 
Figure 25 shows that neither miconazole or exemestane had a significant effect of 
ERELUC reporter activity in response to DHEA or its metabolites in the presence of 
cotransfected ER~. These results strongly suggest that DHEA and the metabolites we 
have added to the cells bind directly to ERa and ER~ to activation of ERELUC 
expression and that transcriptional activation seen is not caused by metabolism of the 
added DHEA or DHEA metabolites to estrogen by aromatase. 
In addition to the transient transfection assays, the metabolites that exhibited 
significant induction of ERELUC were used in a HAP ligand binding assay (Pavlik and 
Coulson, 1976) with recombinant human ERa or ER~ to further examine ligand binding 
to ERa or ER~. Figure 26 shows that in our hands, the IC50 value of E2 for ERa is ~ 10 
nM which is similar to the value reported in various literature (Branham et ai., 2002). 
ADIOL bound to ERa with an IC50 of ~ 1 /-lM. DHEA and DHEA-S bound ERa with 
IC50s of>500 /-lM and 100-500 /-lM respectively. Figure 27 shows that the IC50 of 17~-E2 
for ER~ is ~50 nM. Again, this value is in agreement with previous studies (Branham et 
ai.,2002). Like ERa, ADIOL exhibited significant binding to ER~ with an IC50 of ~50 
nM followed by AD lONE with an IC50 of 50 /-lM. DHEA and 7 .. oxo-DHEA exhibited 
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Figure 24, Effect of P450 inhibitors (non-specific inhibitor, miconazole or aromatase 
inhibitor, exemestane) on ERELUC reporter activity in response to DHEA and 
metabolites in the presence of cotransfected ERa in HEK293 cells, HEK293 cells 
were transfected with ERELUC reporter plasmid and expression vector for human ERa. 
Cells were treated for 24 h with 5 f.lM DHEA metabolite and either 5 f.lM P450 inhibitor, 
miconazole (non-specific P450 inhibitor) or 100 nM aromatase inhibitor, exemestane. 
Cells were harvested and lysates assayed for p-galactosidase and luciferase activities. 
Data represent the mean ± S.D. of three wells. Experiments were repeated three times 
with similar results. None of the results were statistically different. 
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Figure 25. Lack of effect of P450 inhibitors on ERELUC reporter activity in 
response to DHEA and metabolites in the presence of cotralllsfected ER~ in HepG2 
cells. HepG2 cells were transfected with ERELUC reporter plasmid and expression 
vector for human ER~. Cells were treated for 24 h with 5 ~M DHEA metabolite and 
either 5 ~M P450 inhibitor, miconazole (non-specific inhibitor) or 100 nM exemestane 
(aromatase inhibitor). Cells were harvested and lysates assayed for ~-galactosidase and 
luciferase activities. Data represent the mean ± S.D. of three wells. Experiments were 
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Figure 26. Competition curves for DHEA metabolite binding to ERa.. [3H]-17~-
estradiol (E2) is competing for binding to the ER with increasing concentrations of either 
nonradiolabeled E2 or DHEA and metabolites (DHEA-S and ADIOL). Each data point 
represents the mean of two independent binding assays. The competitor concentration 
causing 50% reduction in eH]-E2 binding (ICso) is found at the intersection of the 
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Figure 27. Competition curves for DHEA metabolite binding to ER~. eH]-17~-
estradiol (E2) is competing for binding to the ER with increasing concentrations of either 
nonradiolabeled E2 or DHEA and metabolites (ADIOL, ADIONE, and 7-oxo-DHEA). 
Each data represents the mean of two independent binding assays. The competitor 
concentration causing 50% reduction in eH]-E2 binding (IC50) is found at the intersection 
of the binding curves with the 50% binding line (---------).+, E2; ., DHEA; A, 7-oxo-
DHEA; ., ADIOL; 0, ADIONE 
72 
DISCUSSION 
ER plays an important role in the physiology of many tissues (Couse and Korach, 
2001). Upon binding estrogen or estrogen-like ligands, ER regulates the expression of 
certain genes by binding estrogen responsive elements (EREs), promoters within the 5'-
flanking region of these genes. Estrogens are known to have profound effects on both 
female and male reproductive systems, as well as, important roles in cardiovascular 
system and maintenance of bone tissue (Nilsson and Gustafsson, 2002). Although 
estrogens are purported to playa protective role in certain diseasles such as 
atherosclerosis, osteoporosis, and Alzheimer's disease, estrogens can also promote 
carcinomas in other tissues (Hoskins and Weber, 1994). DHEA has been purported to 
share some of the same beneficial properties as estrogens without the carcinogenic effects 
of estrogen. 
The activation of an ERE-driven 1uciferase reporter by hERa and hER~ was 
examined in response to E2, DHEA and DHEA metabolites. DHEA, DHEA-S and 
ADIOL activated ERa-mediated ERE reporter expression in HEK293 cells, whereas 
DHEA, 7-oxo-DHEA and the cytosolic metabolites, ADIOL and AD lONE activated 
ER~-mediated ERE reporter expression in HepG2 cells. The ER antagonists ICI 182,780 
and 4-OHT blocked the agonist activity ofDHEA and metabolites, whereas the P450 
inhibitor, miconazole, and the aromatase inhibitor, exemestane, failed to inhibit the 
induction ofERELUC. Taken together, these results indicate that agonist activity on 
ERELUC is mediated by a direct interaction ofDHEA and selected metabolites with the 
ligand-binding domain of ERa and ER~. The direct binding of ADIOL to both ERa and 
ER~ was confirmed by ligand binding assay (Figure 26 and Figure 27). However, 
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according to the ligand binding assay, DHEA-S binds ERa weakly and DHEA bound 
even more weakly. DHEA, ADIONE, and 7-oxo-DHEA also bind weakly to ER~. This 
suggests that ADIOL binds to both receptors with relatively high affinity whereas the 
other metabolites activate the ERa and ER~ mediated ERELUC activity by weakly 
binding the receptors. However, it should be noted that since DHEA-S is present in 
physiological concentrations of a log higher than DHEA, exogenous DHEA 
supplementation could possibly increase physiological DHEA-S levels to a point that 
activates ERa. As a result, the possibility for DHEA-S to be a potent ligand for ER (Le 
Bail et at., 1998) as well as other receptors should be considered. 
Interestingly, in addition to E2, the most potent inducer of ERa-mediated 
ERELUC transcriptional activation is ADIOL, while the potent inducer ofER~-mediated 
ERELUC transcriptional activation is ADIONE. Since the ligand-mediated activation of 
ERELUC is more robust with ER~ in HepG2 cells then ERa in HEK293 cells, CHO-K1 
(Chinese hamster ovary) and MDA-MB-231 (breast cancer) cells were transfected with 
both ERs. None of the cell lines examined exhibited both ERa and ER~ mediated 
activation of ERELUC transcriptional activity by E2 and the DHEA metabolites. In 
HepG2 cells, the action of the AF-l domain is greater than that of the AF-2 domain, 
while in HEK293 cells, the activity of the AF-l domain is similar to that of the AF-2 
domain (Metivier et ai., 2001). Since AF-l is known has been found to be stimulated by 
phosphorylation by mitogen-activated protein kinase (MAPK) (Kato et ai., 1995), the 
ER~ mediated activation of ERELUC transcriptional activity by DHEA and metabolites 
were examined in the presence of the MAPK inhibitor, PD98059. There was no 
significant difference in the ERELUC transcriptional activity in the presence or absence 
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of the inhibitor, suggesting that DHEA and metabolite activation of ERa and ER~ 
transcription is not dependent on phosphorylation (data not shown). 
In summary, these studies demonstrate that DHEA and metabolites are able to 
directly activate ERa and ER~ in cell-based assays suggesting that DHEA and 
metabolites mediate the activation of the classic estrogen receptor. These results provide 





Dehydroepiandrosterone (DHEA) is C-19 steroid produced by the adrenal gland of 
humans. DHEA is synthesized from cholesterol by a series of cytochrome P450 mono-
oxygenase and hydroxysteroid dehydrogenase catalyzed reactions. DHEA can also be 
metabolized to androgens and estrogens in steroidogenic tissues where it is then taken up by 
target tissues, such as testes and ovaries, and converted to sex steroids. 
In its sulfated form, DHEA-S, DHEA is the most abundant circulating steroid in 
humans. Plasma DHEA levels are highest in the second or third decade of life, but decline 
significantly in late adulthood. The decline in DHEA levels has be(~n purported to be 
associated with some of the deleterious affects of aging such as memory loss, 
arteriosclerosis, obesity and cancer (Barret-Conner et al., 1999). As a result, DHEA is 
marketed as a "fountain of youth hormone" and sold over-the-counter as a dietary 
supplement. 
Treatment of humans with exogenous DHEA has been suggested to have beneficial 
effects including anti-atherosclerotic properties, enhancement of irrtmune function and 
memory as well as amelioration of diabetes, systemic lupus erythernatosis and obesity 
(Robinzon et al. 1999, Ben-Nathan et al., 1992, and Lapchak et al.,. 2001). In addition, 
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DHEA has been reported to have anti-carcinogenic effects in various organs in rodents 
especially the mammary gland after chemical cancer induction (Mayer, 1998 and Feo et al., 
2000). In contrast, Maggiolini et al. (1999) reported that DHEA and androstendiol (ADIOL) 
directly activate transfected ERa reporter genes as well as stimulate proliferation of breast 
cancer cell lines. Additionally, Calhoun and coworkers (2003) suggest that high DHEA-S 
levels pose a risk factor for breast cancer patients treated with tamoxifen. 
Although DHEA is sold as an over-the-counter supplement and therefore is not 
regulated by the Food and Drug Administration, a physiological role and the mechanism of 
action of DHEA have not been defined to date. Therefore, the mechanism of action of this 
sterol becomes important to study. 
It has been suggested that the mechanism by which DHEA exerts its pleotropic 
effects in humans may involve the metabolism ofDHEA in target tissues to biologically 
active species that are thereby responsible for the various physiological and pharmacological 
effects ofDHEA. In fact, 7-hydroxylated and 7-oxygenated metabolites ofDHEA have been 
reported to have effects in the brain and immune system (Lathe, 2002). Additionally, 16-
hydroxylated metabolite of DHEA has been reported to be the main phenolic steroid during 
pregnancy (Hampl and Starka, 2000) 
In addition to being metabolized to active metabolites, DHEA has also been reported 
to mediate gene expression by serving as a ligand for nuclear receptors. For instance, Ripp et 
at. (2002) demonstrated that in in vitro cell-based assays DHEA and its metabolites ADIOL 
and ADIONE were able to activate the human pregnane X receptor (PXR) which is a nuclear 
receptor involved in the regulation of the CYP3A subfamily of enzymes that catalyze the 
oxidation of endogenous steroids as well as the metabolism of a wider array of drugs. DHEA 
77 
and ADIOL are known to activate another nuclear receptor, peroxisome proliferator activated 
receptor alpha (PP ARa) in vivo (Peters et al., 1996). Recent studies suggest that in addition 
to nuclear receptors, DHEA can activate membrane receptors followed by activation of 
intracellular cell signaling cascades (Liu and Dillon, 2002). 
The overall goal of this project was to investigate the mechartism of action ofDHEA 
as it pertains gene regulation mediated by selected nuclear receptors.. Our hypothesis was 
that DHEA is metabolized to biologically active metabolites that exert their action through 
various receptors and pathways. To begin to address our hypothesis and to investigate the 
metabolism ofDHEA, the liver microsomal metabolism ofDHEA by various species was 
quantified and the P450s responsible for DHEA metabolism were elucidated. A gas 
chromatography-mass spectrometry method was developed for identification and 
quantification ofDHEA and metabolites. The DHEA metabolites produced by liver 
microsomal cytochrome P450s exhibited stereo- and regio-selectivity. 
7a-OH-DHEA was the major metabolite formed by rat, hamster and pig followed by 
16a-OH-DHEA. Several unidentified metabolites were formed by hamster liver 
microsomes, and androstenedione was produced only by pig microsomes. Liver microsomal 
fractions from one human demonstrated that DHEA was oxidatively metabolized to 7a-OH-
DHEA, 16a-OH-DHEA, and a previously unidentified metabolite, 7~-OH-DHEA. Other 
human microsomal fractions exhibited much lower rates of metabolism but with similar 
metabolic profiles. 
Using expressed cytochrome P450 preparations, CYP3A4 and CYP3A5 were shown 
to be the cytochromes P450s responsible for production of7a-OH-DHEA, 7~-OH-DHEA 
and 16a-OH-DHEA in adult liver microsomes, whereas the fetal form CYP3A 7 produced 
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16a-OH and 7~-OH-DHEA. CYP3A23 uniquely formed 7a-OH-DHEA, whereas other 
P450s, CYP2Bl, CYP2Cl1 and CYP2D1 were responsible for 16a-OH-DHEA metabolite 
production in rat liver microsomal fractions. These metabolites could potentially serve as 
activators of nuclear receptors or be utilized in following the developmental pattern of 
CYP3A isoforms. 
In order to examine the DHEA-mediated activation of ERa and ER~, DHEA and its 
metabolites were tested for their ability to activate ERa and ER~ in transient transfection 
assays of HepG2 and HEK293 cells. Two cell types were used because ERa displayed high 
basal rate in HepG2 cells, whereas ER~ was not well activated by 17~-estradiol in cells other 
than HepG2 cells. DHEA, DHEA-S and ADIOL activated ERa-mediated ERE reporter 
expression in HEK293 cells and DHEA, 7-oxo-DHEA, ADIOL, and ADIONE activated 
ER~-mediated ERE reporter expression in HepG2 cells. The anti estrogens ICI 182,780 and 
4-hydroxytamoxifen blocked the agonist activity ofDHEA and metabolites suggesting that 
the agonist activity of DHEA and metabolites is mediated by a direct interaction between 
ligand and ER. The general P450 inhibitor, miconazole and exemestane, an aromatase 
inhibitor, decreased E2 and DHEA-mediated ERELUC activities mimicked by ERa to the 
same extent. Neither miconazole nor exemestane inhibited ER~ activated ERELUC 
transcription with E2, DHEA or DHEA metabolites. Taken together, these results suggest 
that DHEA and metabolites do not exert their activity by being metabolized to estrogens in 
this cell-based assay, but serve as direct ligands for ERa and ER~. This was demonstrated 
directly in competitive binding assays with ERa and ER~. 
DHEA and ADIOL were inducers of both ERa- and ERp-mediated ERELUC 
transactivation. However, DHEA-S was an inducer of ERa, while ADIONE and 7-oxo-
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DHEA were inducers ofERp. A ligand-binding assay confirmed the direct binding of 
ADIOL to both ERa and ERp. However, the other metabolites had a higher ICso values for 
their respective receptors, suggesting a weaker binding of the other metabolites to ERa and 
ERp. Since DHEA-S has relatively higher circulating concentrations in the human, its 
potential role as a potent ligand for nuclear receptors should be considered. 
In summary, this study demonstrates that DHEA is extensively metabolized by liver 
microsomal fractions and the human produces a unique metabolite, 7P-OH-DHEA. These 
data support the hypothesis that the metabolism ofDHEA to various metabolites may playa 
role in the biological action ofDHEA. Additionally, DHEA and metabolites were also 
shown to directly activate ERa and ERP in in vitro cell-based assays, suggesting DHEA 
mediates the activation of the classic estrogen receptor. Ultimately, the results of these 
studies provide new insights into the many mechanisms of action described for DHEA and 
demonstrate that DHEA exerts its biological effects through metabolism to mUltiple active 















Figure 28. DHEA action is mediated by multiple receptors and metabolites. 
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APPENDICES 
LIST OF ABBREVIATIONS 







ADIOL: androstendiol (androst-5-ene-3, 17-diol) 
ADIONE: androstenedione (androst-5-ene-3,17-dione) 
AF -1 : activation function-l 
AF-2: activation function-2 
BSTF A-TMS: N,O-bis(trimethylsi1yl)trifluoroacetamide 
CAR: constitutive androstane receptor 
CYP: cytochrome P450 
DBD: DNA binding domain 
D HEA: deh ydroepiandrosterone (3 ~ -hydroxy-androst -5 -ene-l 7 ·-one) 
DHEA-S: DHEA 3~-sulfate 




EET: epoxyeicosatrienoid acid 
EI: electron ionization 
ER: endoplasmic reticulum 
ER: estrogen receptor 
ERE: estrogen response element 
ETIO: etiocholanolone 
FAD: flavin adenine dinucleotide 
FDA: Food and Drug Administration 
FMN: flavin mononucleotide 
FXR: farnesoid X receptor 
GCIMS: gas chromatography-mass spectrometry 
HAP: hydroxyapatite 
HETE: hydroxyeicosatetraenoic acid 
HPETE: hydroeperoxyeicosateraenoic acid 
LC-MS: liquid chromatography-mass spectrometry 
LBD: ligand binding domain 
LXR: liver X receptor 
MAPK: mitogen activated protein kinase 
MOX: methoxyamine· HCl 
NADPH: nicotinamide adenine dinucleotide phosphate 
NAD: nicotinamide adenine dinucleotide 
98 
P450: cytochrome P450 
P450 oxidoreductase: NADPH/cytochrome P450 oxidoreductase 
PKA: protein kinase A 
PKC: protein kinase C 
PMSF: phenyl methyl sulfonyl fluoride 
PP AR: peroxisome proliferator activated receptor 
PPRE: PP ARa response element 
RXR: retinoic acid receptor 
SD: standard deviation 
TR: thyroid hormone receptor 
VDR: vitamin D receptor 
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